Company news

BeOne Medicines Ltd. news in 2025

BeOne Medicines Ltd.'s news releases, calls and decks from 2025, newest first.

View company

BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 23, 2025

BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma

December 18, 2025

BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia

December 8, 2025

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies

December 7, 2025

U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

November 26, 2025

BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025

November 20, 2025

Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma

November 17, 2025

Report for Q3 2025

November 12, 2025

BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates

November 6, 2025

BeOne Medicines to Present at Upcoming Investor Conferences

October 28, 2025

BeOne Medicines to Announce Third Quarter 2025 Financial Results on November 6

October 22, 2025

BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025

October 20, 2025

BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA

October 13, 2025

Announcement on Progress in Litigation Involving the Company

October 8, 2025

Announcement on Abnormal Fluctuations in Stock Trading

September 2, 2025

BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)

August 29, 2025

European Commission Approves TEVIMBRA® as Neoadjuvant/Adjuvant NSCLC Treatment Ahead of Late-Breaking Data Presentation at WCLC 2025

August 27, 2025

BeOne to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

August 26, 2025

BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million

August 25, 2025

Announcement on Convening the 2025 Semi-annual Performance Briefing

August 22, 2025

European Commission Approves Tablet Formulation of BeOne Medicines’ BRUKINSA® for All Approved Indications

August 21, 2025

Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1%

August 20, 2025

BeOne Medicines Announces Second Quarter 2025 Financial Results and Business Updates

August 6, 2025

BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstrom’s Macroglobulinemia

July 31, 2025

BeOne Medicines Receives Positive CHMP Opinion for TEVIMBRA® in Neoadjuvant/Adjuvant NSCLC Treatment

July 28, 2025

BeOne Medicines to Announce Second Quarter 2025 Financial Results on August 6

July 16, 2025

European Commission Approves TEVIMBRA® in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal Carcinoma

July 10, 2025

BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day

June 26, 2025

BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA®

June 25, 2025

BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025

June 12, 2025

U.S. FDA Approves Tablet Formulation of BeOne’s BRUKINSA® for All Approved Indications

June 11, 2025

BeOne Medicines to Host Investor R&D Day Webcast on June 26, 2025

June 11, 2025

BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 2025

June 2, 2025

BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 2025

May 31, 2025

BeOne Medicines Launches Following Redomiciliation to Switzerland, Marking a New Chapter in Global Oncology

May 27, 2025

BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Nasopharyngeal Cancer

May 27, 2025

BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors

May 22, 2025

BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation

May 14, 2025

BeiGene to Present at the RBC Capital Markets Global Healthcare Conference

May 13, 2025

BeiGene Announces First Quarter 2025 Financial Results and Business Updates

May 7, 2025

U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene

April 29, 2025

2024 Annual Report

April 28, 2025

Announcement on Convening the 2024 Annual Performance Briefing

April 18, 2025

BeiGene to Announce First Quarter 2025 Financial Results on May 7

April 17, 2025

Notice on Convening the 2025 Annual General Meeting

April 7, 2025

BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program

April 3, 2025

BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

March 31, 2025

Announcement on Renewing Engagement of Audit Institution for 2025

March 24, 2025

Announcement on the Equity Registration Date for the 1st Extraordinary General Meeting in 2025

March 11, 2025

Notice on Convening the 1st Extraordinary General Meeting (Shareholders' Special Meeting) in 2025

March 10, 2025

Older news releases →

Calls in 2025

Decks in 2025